{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:34:32Z","timestamp":1790192072878,"version":"4.1.0"},"reference-count":55,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,5,15]],"date-time":"2009-05-15T00:00:00Z","timestamp":1242345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:p>Obesity is associated with increased risk of conditions such as hypertension, dyslipidaemia, diabetes mellitus, and obstructive sleep apnoea. Pharmacotherapy for obesity should be considered in combination with lifestyle changes in obese patients, or overweight patients with other conditions that put them at risk of developing heart disease. Sibutramine and orlistat are the only two anti\u2010obesity medications approved for long\u2010term use. Sibutramine is a serotonergic and adrenergic drug that reduces food intake. Orlistat is a gastrointestinal lipase inhibitor that interferes with fat absorption. However, it commonly causes flatulence and diarrhoea. Rimonabant is the first of a series of endocannabinoid receptor antagonists. It was approved by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMEA) as an adjunct to diet and exercise in treating obesity in 2006. However, despite the extensive clinical trial data, EMEA announced in 2008 that it has recommended suspension of rimonabant because of its psychiatric side effects. Studies evaluating the long\u2010term safety and efficacy of anti\u2010obesity agents are needed.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2009.03453.x","type":"journal-article","created":{"date-parts":[[2009,5,15]],"date-time":"2009-05-15T12:02:53Z","timestamp":1242388973000},"page":"804-810","source":"Crossref","is-referenced-by-count":69,"title":["Pharmacotherapy for obesity"],"prefix":"10.1111","volume":"68","author":[{"given":"Mingfang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard M. Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,27]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.1.76"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjr.0000114707.27531.48"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.1549"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.67.5.968"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)10004-6"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010492"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.168"},{"key":"e_1_2_5_9_2","volume-title":"Obesity: Preventing and managing the global epidemic","author":"World Health Organization","year":"1998"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1995.tb00124.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-7-200504050-00011"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.14.1837"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022637"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-10-200405180-00006"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050156"},{"key":"e_1_2_5_16_2","first-page":"397","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"Goldstein DJ","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_5_17_2","first-page":"s5","article-title":"The beneficial effects of modest weight loss on cardiovascular risk factors","volume":"21","author":"Van Gaal LF","year":"1997","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)90009-9"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep0092"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629040-00001"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00016"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801889"},{"key":"e_1_2_5_23_2","first-page":"300","article-title":"A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice","volume":"3","author":"Valle\u2010Jones JC","year":"1983","journal-title":"Pharmatherapeutica"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-7-200504050-00012"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1467-789x.2000.00020.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.9.994"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856060-00019"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802887"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.10.1629"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.02.002"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm217"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66348-9"},{"key":"e_1_2_5_34_2","unstructured":"European Medicines Agency.The European Medicines Agency recommends suspension of the marketing authorization of Acomplia. [press release] Oct 23 2008. Available at:http:\/\/www.emea.europa.eu(Doc. Ref.: EMEA\/CHMP\/537777\/2008)."},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1495"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66374-X"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.7.761"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044537"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69571-8"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.2174\/157489008786264014"},{"key":"e_1_2_5_41_2","first-page":"s12","article-title":"Mode of action of orlistat","volume":"21","author":"Guerciolini R","year":"1997","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.104"},{"key":"e_1_2_5_43_2","unstructured":"US Food and Drug Administration.FDA approves orlistat for obesity. [press announcement] Febuary 7 2007. Available athttp:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2007\/NEW01557.html."},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.1.155"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200510000-00001"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-5299.2005.03827.x"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2005.01723.x"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.23.2873"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP.12.1.18"},{"key":"e_1_2_5_50_2","first-page":"16","article-title":"Review of anti\u2010obesity medications currently under development","volume":"15","author":"Hirsch B","year":"2000","journal-title":"Am J Bar Med"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2136"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.118737"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2037"},{"key":"e_1_2_5_54_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1742-1241.2007.01441.x","article-title":"Antidiabetic medications in overweight\/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin\u2010based treatment on body weight","volume":"154","author":"Bonora E","year":"2007","journal-title":"Int J Clin Pract Suppl"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.crd.0000233903.57946.fd"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61246-5"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2009.03453.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2009.03453.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:08:31Z","timestamp":1697418511000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2009.03453.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,27]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1365-2125.2009.03453.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03453.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,27]]}}}